Opus Genetics gets FDA alignment on Phase 3 eye gene therapy trial

July 6, 2026 7:01 AM

Opus Genetics, Inc. (Nasdaq: IRD) announced it has reached alignment with the U.S. Food and Drug Administration on the design ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found